- Previous Close
3.3000 - Open
3.3000 - Bid 3.3200 x 40000
- Ask 3.4700 x 40000
- Day's Range
3.3000 - 3.3000 - 52 Week Range
2.6400 - 6.5600 - Volume
264 - Avg. Volume
7,423 - Market Cap (intraday)
2.147B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
9.19 - EPS (TTM)
0.3700 - Earnings Date Apr 23, 2025
- Forward Dividend & Yield 0.21 (6.12%)
- Ex-Dividend Date Apr 4, 2025
- 1y Target Est
--
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
www.hypera.com.br--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HYPMY
View MorePerformance Overview: HYPMY
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is IBOVESPA (^BVSP) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HYPMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HYPMY
View MoreValuation Measures
Market Cap
2.12B
Enterprise Value
3.45B
Trailing P/E
9.21
Forward P/E
11.14
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.66
Price/Book (mrq)
1.01
Enterprise Value/Revenue
2.67
Enterprise Value/EBITDA
8.91
Financial Highlights
Profitability and Income Statement
Profit Margin
17.88%
Return on Assets (ttm)
4.57%
Return on Equity (ttm)
11.29%
Revenue (ttm)
7.44B
Net Income Avi to Common (ttm)
1.33B
Diluted EPS (ttm)
0.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
1.74B
Total Debt/Equity (mrq)
77.65%
Levered Free Cash Flow (ttm)
1.31B